Should Value Investors Buy Encore Capital Group (ECPG) Stock? — Positive
ECPG Zacks Investment Research — May 26, 2025Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Brokers Suggest Investing in Veeva (VEEV): Read This Before Placing a Bet — Negative
VEEV Zacks Investment Research — May 26, 2025The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Is Salesforce.com (CRM) a Buy as Wall Street Analysts Look Optimistic? — Neutral
CRM Zacks Investment Research — May 26, 2025The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Is It Worth Investing in Take-Two (TTWO) Based on Wall Street's Bullish Views? — Positive
TTWO Zacks Investment Research — May 26, 2025When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Analysts Think PulteGroup (PHM) Is a Good Investment: Is It? — Positive
PHM Zacks Investment Research — May 26, 2025Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Analysts Think Arista Networks (ANET) Is a Good Investment: Is It? — Neutral
ANET Zacks Investment Research — May 26, 2025The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Is StoneCo (STNE) a Buy as Wall Street Analysts Look Optimistic? — Positive
STNE Zacks Investment Research — May 26, 2025Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is It Worth Investing in PDD Holdings Inc. Sponsored ADR (PDD) Based on Wall Street's Bullish Views? — Positive
PDD Zacks Investment Research — May 26, 2025Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is It Worth Investing in Constellation Energy Corporation (CEG) Based on Wall Street's Bullish Views? — Neutral
CEG Zacks Investment Research — May 26, 2025The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

GigaCloud Technology Inc. (GCT) Is Considered a Good Investment by Brokers: Is That True? — Positive
GCT Zacks Investment Research — May 26, 2025Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Wall Street Analysts Think AGNC Investment (AGNC) Is a Good Investment: Is It? — Neutral
AGNC Zacks Investment Research — May 26, 2025The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

G-III Stock's Low P/E Ratio Signals Value Opportunity: Here's Why — Neutral
GIII Zacks Investment Research — May 26, 2025GIII's low P/E signals value amid global growth and digital investment, though rising costs and soft 2026 guidance pressure profit expectations.

NetApp Gears Up to Post Q4 Earnings: What's in the Offing? — Positive
NTAP Zacks Investment Research — May 26, 2025NTAP's fiscal Q4 performance is likely to have benefited from strength across its all-flash storage products amid forex woes and the global Public sector downtrend.

Down 18.4% in 4 Weeks, Here's Why You Should You Buy the Dip in P3 Health Partners (PIII) — Positive
PIII Zacks Investment Research — May 26, 2025The heavy selling pressure might have exhausted for P3 Health Partners (PIII) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Oxford Square Capital (OXSQ) Loses 7.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner — Negative
OXSQ Zacks Investment Research — May 26, 2025The heavy selling pressure might have exhausted for Oxford Square Capital (OXSQ) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Despite a sharp decline in sales of COVID-19 blockbuster Veklury, Gilead Sciences once again beat consensus revenue and EPS forecasts. The drugs whose performance impressed me greatly in Q1 2025 and which played a key role in maintaining Gilead's EBIT margin above 38% are Biktarvy, Livdelzi, and Yescarta. Meanwhile, the sales dynamics of its oncology franchise left me with mixed feelings, including due to the increasing pressure from more effective CAR T-cell therapies, bispecific antibodies, and ADCs.

Reasons to Include Curtiss-Wright Stock in Your Portfolio Right Away — Positive
CW Zacks Investment Research — May 26, 2025CW is a solid pick in the aerospace defense equipment industry, given its growth prospects, better debt management and shareholder-friendly initiatives.

Bilibili (BILI) Just Overtook the 200-Day Moving Average — Positive
BILI Zacks Investment Research — May 26, 2025From a technical perspective, Bilibili (BILI) is looking like an interesting pick, as it just reached a key level of support. BILI recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

Compared to Estimates, Sunrun (RUN) Q1 Earnings: A Look at Key Metrics — Neutral
RUN Zacks Investment Research — May 26, 2025While the top- and bottom-line numbers for Sunrun (RUN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Cenovus (CVE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates — Neutral
CVE Zacks Investment Research — May 26, 2025While the top- and bottom-line numbers for Cenovus (CVE) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
